乳腺癌耐药相关蛋白在乳腺癌的表达及与临床病理参数相关性

目的探讨原发性乳腺癌中乳腺癌耐药相关蛋白(BCRP)表达与临床指标及病理参数的相关性。方法采用免疫组织化学方法检测BCRP及雌激素受体α(ERα)、孕激素受体(PR)、HER-2、P53等病理参数的表达,应用Kruskal-Wallis秩和检验和Spearman相关性检验分析BCRP与临床指标及病理参数的相关性。结果原发性乳腺癌中BCRP表达阳性率64.39%,癌旁组织中BCRP表达阳性率33.33%,两者相比有显著性差异(X~2=9.323,P=0.002);BCRP表达水平与患者年龄、病理类型、临床分级及淋巴结转移无关,而与患者是否绝经有关,未绝经患者乳腺癌组织中BCRP表达水平显著高于已绝经患者(X~2=6.928,P=0.008);BCRP表达水平与ERα(r=0.204,P=0.019)和HER-2表达水平呈正相关(r=0.246,P=0.004),与PR、P53表达水平不具有相关性。结论乳腺癌中BCRP蛋白表达水平明显高于癌旁正常组织,其表达强度与与患者体内雌激素水平及ERα及HER-2强度正相关。

The Correlation between the Expression of BCRP and Clinical Pathological Parameters in Breast Cancer

Objective To study the correlation of the expression of breast cancer resistance protein(BCRP)with clinical index and pathological parameters such as estrogen receptor(ER),progestogen receptor(PR),HER-2 and P53 in breast cancer.Methods The expressions of BCRP,ER,PR,HER-2 and P53 proteins were examined using immunohistochemistry.The correlations of BCRP with the clinical data as well as the pathological parameters were analyzed by Kruskal-Wallis nonparametric test and Spearman correlate test.Results The positive expression rate of BCRP in breast cancer was significantly higher than that in the adjacent normal tissues(64.39% vs 33.33%,X~2=9.323,P=0.002).The expression of BCRP in breast cancer tissues was not associated with histological types,age,clinical stage or lymph node metastases state,but significantly different between the pre menopause and the post-menopause patients(X~2=6.928, P=0.008).The expression of BCRP was positively correlated with the expressions of ERα(r=0.204,P=0.019)or HER-2 (r=0.246,P=0.004)respectively,but not correlated with P53 or PR.Conclusion The overexpression of BCRP in breast cancer has positively correlation with the estrogen level as well as the expressions of ERαand HER-2.